Leite KRM - Search Results

1

Can we use Ki67 expression to predict prostate cancer aggressiveness?

Maia R, Santos GAD, Reis S, Viana NI, Pimenta R, Guimarães VR, Recuero S, Romão P, Leite KRM, Srougi M, Passerotti CC. Maia R, et al. Among authors: leite krm. Rev Col Bras Cir. 2022 Jul 1;49:e20223200. doi: 10.1590/0100-6991e-20223200-en. eCollection 2022. Rev Col Bras Cir. 2022. PMID: 35792806 Free PMC article.

2

Low clinical stage renal cell carcinoma: relevance of microvascular tumor invasion as a prognostic parameter.

Gonçalves PD, Srougi M, Dall'lio MF, Leite KR, Ortiz V, Hering F. Gonçalves PD, et al. J Urol. 2004 Aug;172(2):470-4. doi: 10.1097/01.ju.0000130582.31467.30. J Urol. 2004. PMID: 15247705

3

The role of HER2/neu, BCL2, p53 genes and proliferating cell nuclear protein as molecular prognostic parameters in localized prostate carcinoma.

Fonseca GN, Srougi M, Leite KR, Nesrallah LJ, Ortiz V. Fonseca GN, et al. Sao Paulo Med J. 2004 May 6;122(3):124-7. doi: 10.1590/s1516-31802004000300009. Epub 2004 Sep 16. Sao Paulo Med J. 2004. PMID: 15448811 Free article.

4

[Prostate cancer dedifferentiation following antiandrogen therapy: a morphological finding or an increased tumor aggressiveness?].

Moritz R, Srougi M, Ortiz V, Leite KR, Nesrallah L, Dall'Oglio M, Sant'Anna AC. Moritz R, et al. Rev Assoc Med Bras (1992). 2005 Mar-Apr;51(2):117-20. doi: 10.1590/s0104-42302005000200020. Epub 2005 Jun 7. Rev Assoc Med Bras (1992). 2005. PMID: 15947826 Free article. Portuguese.

5

Pure sarcomatous recurrence of clear cell renal carcinoma following radical nephrectomy and dendritic cell vaccination.

Antunes AA, Dall'Oglio MF, Barbuto JA, Leite KR, Srougi M. Antunes AA, et al. Sao Paulo Med J. 2006 May 4;124(3):161-2. doi: 10.1590/s1516-31802006000300011. Sao Paulo Med J. 2006. PMID: 17119695 Free article.

6

Prostate cancer detection at rebiopsy after an initial benign diagnosis: results using sextant extended prostate biopsy.

Leite KR, Camara-Lopes LH, Cury J, Dall'oglio MF, Sañudo A, Srougi M. Leite KR, et al. Clinics (Sao Paulo). 2008 Jun;63(3):339-42. doi: 10.1590/s1807-59322008000300009. Clinics (Sao Paulo). 2008. PMID: 18568243 Free PMC article.

7

Cdx2, cytokeratin 20, thyroid transcription factor 1, and prostate-specific antigen expression in unusual subtypes of prostate cancer.

Leite KRM, Mitteldorf CATS, Srougi M, Dall'Oglio MF, Antunes AA, Pontes J Jr, Camara-Lopes LH. Leite KRM, et al. Ann Diagn Pathol. 2008 Aug;12(4):260-266. doi: 10.1016/j.anndiagpath.2007.11.001. Epub 2008 Apr 18. Ann Diagn Pathol. 2008. PMID: 18620992

8

Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer.

Dos Reis ST, Pontes J Jr, Villanova FE, Borra PM, Antunes AA, Dall'oglio MF, Srougi M, Leite KR. Dos Reis ST, et al. J Urol. 2009 May;181(5):2320-5. doi: 10.1016/j.juro.2009.01.012. Epub 2009 Mar 19. J Urol. 2009. PMID: 19303106

9

Association between integrin expression and prognosis in localized prostate cancer.

Pontes-Júnior J, Reis ST, de Oliveira LC, Sant'anna AC, Dall'oglio MF, Antunes AA, Ribeiro-Filho LA, Carvalho PA, Cury J, Srougi M, Leite KR. Pontes-Júnior J, et al. Prostate. 2010 Aug;70(11):1189-95. doi: 10.1002/pros.21153. Prostate. 2010. PMID: 20564421

10

Polymorphisms of the matrix metalloproteinases associated with prostate cancer.

Dos Reis ST, Villanova FE, De Andrade PM, Pontes J, Silva IA, Canavez FC, Sañudo A, Srougi M, Leite KR. Dos Reis ST, et al. Mol Med Rep. 2008 Jul-Aug;1(4):517-20. Mol Med Rep. 2008. PMID: 21479442

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

187 results

Search Page